Search
Rimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalRimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commissio...
Categories: MATE 1 Inhibitors, P-glycoprotein substratesFedratinib
go.drugbank.com/drugs/DB12500ApprovedInvestigationalFedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsOmaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigational[A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress. … Omaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory properties.
Synonyms: Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-Categories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 SubstratesBatefenterol
go.drugbank.com/drugs/DB12526InvestigationalBatefenterol has been used in trials studying the treatment of Pulmonary Disease, Chronic Obstructive.
Categories: Heterocyclic Compounds, 2-Ring, Adrenergic beta-2 Receptor AgonistsTradipitant
go.drugbank.com/drugs/DB12580ApprovedInvestigationalTradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors. … [L54903] NK-1 receptors are expressed in the brainstem and nucleus tractus solitarius, which receives emetogenic signals from various stimuli including dizziness and vertigo.
Synonyms: (2-(1-(3,5-BIS(TRIFLUOROMETHYL)BENZYL)-5-PYRIDIN-4-YL-1H-1,2,3-TRIAZOL-4-YL)PYRIDIN-3-YL)(2-CHLOROPHENYL)METHANONE, METHANONE, (2-(1-((3,5-BIS(TRIFLUOROMETHYL)PHENYL)METHYL)-5-(4-PYRIDINYL)-1H-1,2,3-TRIAZOL-4-YL)-3-PYRIDINYL)(2-CHLOROPHENYL)-Categories: Substance P/Neurokinin-1 Receptor Antagonist, P-glycoprotein substratesAsciminib
go.drugbank.com/drugs/DB12597ApprovedInvestigationalAsciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). … More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSisomicin
go.drugbank.com/drugs/DB12604InvestigationalSisomicin has been used in trials studying the treatment of Pyoderma.
Synonyms: (2S-CIS)-4-O-(3-AMINO-6-(AMINOMETHYL)-3,4-DIHYDRO-2H-PYRAN-2-YL)-2-DEOXY-6-O-(3-DEOXY-4-C-METHYL-3-(METHYLAMINO)-.BETA.-L-ARABINOPYRANOSYL)-D-STREPTAMINE, O-3-DEOXY-4-C-METHYL-3-(METHYLAMINO)-.BETA-L-ARABINOPYRANOSYL-(1->4)-O-(2,6-DIAMINO-2,3,4,6-TETRADEOXY-.ALPHA.-D-GLYCERO-HEX-4-ENOPYRANOSYL-(1->6))-2-DEOXY-L-STREPTAMINECategories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic IndexPlazomicin
go.drugbank.com/drugs/DB12615ApprovedThe structure of plazomicin was established via appending hydroxylaminobutyric acid to [DB12604] at position 1 and 2-hydroxyethyl group at position 6' [A33942]. … Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from [DB12604].
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsAmuvatinib
go.drugbank.com/drugs/DB12742InvestigationalAmuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. … Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.
Synonyms: 1-Piperazinecarbothioamide, N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro(3,2-d)pyrimidin-4-yl-, 4-[1]Benzofuro[3,2-D]Pyrimidin-4-Yl-N-(1,3-Benzodioxol-5-Ylmethyl)Piperazine-1-CarbothioamideCategories: Heterocyclic Compounds, 1-RingZoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigational[A274938,L54748] It is indicated as a single-dose oral therapy for the treatment of uncomplicated urogenital gonorrhea. … Gonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates